PIR and neoplasm: piR‐55490 promotes the degradation of mammalian targets of rapamycin via direct interaction, thereby diminishing tumor cell proliferation.[15] Another tumor suppressor, piR‐211106, reverses cisplatin resistance in LUAD cells via interaction with pyruvate carboxylase.[16] Notably, piRNAs are more stable due to their protective 2′‐O‐methylation modification at the 3′ ends, which shield them from nucleolytic degradation.[17] A diagnostic panel consisting of two piRNAs, piR‐hsa‐26925 and piR‐hsa‐5444, was found to be elevated in LUAD patients compared to healthy controls.